Sequential measurement of BCR-ABL1 mRNA levels by reverse transcription quantitative polymerase chain reaction (RT-qPCR) is embedded in the management of patients with chronic myeloid leukaemia (CML), and has played an important role in the remarkable improvement in patient outcomes seen in this disease. As a provider of external quality assessment (EQA) in this area, UK NEQAS for Leucocyte Immunophenotyping (UKNEQAS LI) has a unique perspective on the changing face of BCR-ABL1 testing in CML. To assess the impact of technical standardisation and the development of the International Scale (IS) upon the accuracy of BCR-ABL1 testing, we reviewed EQA trial data from 2007 to 2015. Comparison of participant results identified considerable variability at both high and low levels of disease, including therapeutically important decision points; however, results converted to the IS showed less variability compared to unconverted data sets. We also found that different methods of converting to the IS produce consistently different median results within UKNEQAS LI IS data sets. This data suggests that whilst the development of the IS has improved the comparability of results between centres, there is still the need for further improvement in the processes of converting raw results to the IS in order to fully realise the benefits of molecular monitoring of CML.
Summary
Sequential measurement of BCR-ABL1 mRNA levels by reverse transcription quantitative polymerase chain reaction (RT-qPCR) is embedded in the management of patients with chronic myeloid leukaemia (CML), and has played an important role in the remarkable improvement in patient outcomes seen in this disease. As a provider of external quality assessment (EQA) in this area, UK NEQAS for Leucocyte Immunophenotyping (UKNEQAS LI) has a unique perspective on the changing face of BCR-ABL1 testing in CML. To assess the impact of technical standardisation and the development of the International Scale (IS) upon the accuracy of BCR-ABL1 testing, we reviewed EQA trial data from 2007 to 2015. Comparison of participant results identified considerable variability at both high and low levels of disease, including therapeutically important decision points; however, results converted to the IS showed less variability compared to unconverted data sets. We also found that different methods of converting to the IS produce consistently different median results within UKNEQAS LI IS data sets. This data suggests that whilst the development of the IS has improved the comparability of results between centres, there is still the need for further improvement in the processes of converting raw results to the IS in order to fully realise the benefits of molecular monitoring of CML.
Keywords: BCR-ABL1, external quality assessment, quality, chronic myeloid leukaemia, reverse transcription quantitative polymerase chain reaction.
Since the Philadelphia (Ph) chromosome was identified as the first chromosomal abnormality to be linked to a human cancer by Peter Nowell and David Hungerford in 1961 (Nowell & Hungerford, 1961) , chronic myeloid leukaemia (CML) has become a paradigm for what is possible when advances in both biotechnology and 'designer' drug development are successfully harnessed. BCR-ABL1, the oncogenic product of the translocation that gives rise to the Ph chromosome, is not only a therapeutic target in CML but also serves as a specific marker of the malignant clone that can be used to track the response of individual patients to treatment. Due to the diversity of BCR-ABL1 genomic DNA breakpoints, such molecular monitoring is generally performed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) to detect and quantify BCR-ABL1 mRNA in peripheral blood samples. This technique is capable of estimating disease levels over several orders of magnitude.
The International Randomized Study of Interferon and STI571 (IRIS) study formally demonstrated the superiority of imatinib over interferon-based regimens (O'Brien et al, 2003) . In this trial, RT-qPCR analysis was performed in three centres that used different laboratory protocols. However, the large differences in median % BCR-ABL1/reference gene values between the three centres prompted the need for an urgent alignment of their results. As no independent reference or calibration materials were available, an arbitrary decision was made to normalise all results to a 'standardised baseline' derived from a shared set of 30 pre-treatment CML samples. Results were expressed as a log reduction from the standardised baseline and led to improved data comparison between the three centres. This normalisation process, used in the IRIS trial, subsequently formed the basis of the International Scale (IS) for BCR-ABL1 measurement (Hughes et al, 2006) . However, rather than using a log reduction, the IS expresses detectable disease as a percentage, with 100% BCR-ABL IS defined as the IRIS standardised baseline and 0Á1% BCR-ABL IS corresponding to a 3-log reduction from the baseline (equating to a major molecular response; MMR).
Unfortunately, adoption of the IS by routine testing laboratories has proved challenging. The initial approach to generate results on the IS was via the establishment of a 'laboratory-specific conversion factor' by sample exchange with a reference laboratory (Branford et al, 2008) . Following analysis of a set of patient samples in both centres, the estimated mean bias between the two methods is calculated and the derived conversion factor serves to align the results of the field laboratory to the reference laboratory. A second set of samples is then used to validate the conversion factor. Several national reference laboratories have been established to propagate IS conversion factors but, whilst this methodology has been fully validated, it is time consuming, expensive and has a relatively low success rate [in the original study only 58% of laboratories who began the process ended up with validated conversion factors (Branford et al, 2008) ]. In addition, any change in key components within the assay (e.g. platform, Taq enzyme, primers, probes) requires that the IS conversion factor needs to be re-established.
Recently, the first World Health Organisation (WHO) International Genetic Reference Panel for quantification of BCR-ABL1 mRNA (White et al, 2010 ) was created to help provide an alternative to sample exchange. The panel, produced by a collaboration between The National Institute for Biological Standards and Control (NIBSC) and the National Genetics Reference Laboratory (Wessex), consists of freeze dried K562/HL60 cell line mixtures with IS values assigned following an international field trial. The panel has been made available to manufacturers so that secondary reference materials and testing kits can be calibrated, resulting in the availability of IS-calibrated kits.
The United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping (UKNEQAS LI), an International Organization for Standardisation (ISO) 17043 (ISO, 2010) accredited programme, has been providing external quality assessment (EQA) to laboratories undertaking BCR-ABL1 RT-qPCR analysis since 2007 and currently has 190 active international participants from Europe, Africa, South East Asia, the Middle East, Australasia and the Americas. Participation in an ISO 17043 accredited EQA/proficiency testing (EQA/PT) programme is a requirement, where such a programme exists, for laboratories wishing to attain ISO 15189 accreditation (ISO, 2012) . We have reviewed UKNEQAS LI's BCR-ABL1 quantification EQA data set in order to evaluate the impact of the IS upon technical standardisation and ascertain if this has improved accuracy and precision of BCR-ABL1 testing in CML in our cohort.
Methods
Three sets of EQA samples were issued to participants per annum with each comprising of two lyophilised cell line samples containing a mix of BCR-ABL1 (e14a2) positive K562 cells in a background of BCR-ABL1 negative HL60 cells. K562 and HL60 were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany) . HL60 and K562 cultures tested negative for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, cytomegalovirus, Epstein-Barr virus, human T-lymphotropic virus type I and II, human herpes virus 8, and mycoplasma by PCR. Cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (both from Gibco ThermoFisher, Waltham, MA, USA). Pre-defined dilutions of K562 cells in HL60 cells were then prepared and freeze dried in 3-ml glass ampoules to contain 10-20 9 10 6 cells. Samples were dried for 24 h.
Prior to distribution to ensure sample quality and homogeneity, a minimum of three selected samples were subjected to (phenol chloroform) RNA extraction, cDNA synthesis and BCR-ABL1 quantification. This was performed using the Ipsogen BCR-ABL1 Mbcr kit (Qiagen, Hilden, Germany) and the 7500 RQ-PCR machine (Applied Biosystems, Waltham, MA, USA). Analysis was performed in-line with UK recommendations (Foroni et al, 2011) . Sample quality was defined as RNA optical density (OD) 260/280 ratio of between 1Á8 and 2Á2 and ABL1 levels >10 000 per replicate. Replicate values must be within 1Á2-fold of each other (Cross, 2009 ). Stability of trial samples was ensured by measuring ABL1 levels on a further three vials at trial closure. Participants in the programme were asked to measure the % BCR-ABL1/reference gene levels in each sample using their normal laboratory protocols and report results obtained (either converted to the IS, unconverted or both) as well as certain methodological details. Due to the difficulty and expense of producing EQA materials calibrated to the IS, plus the fact that participants do not all use the same reference gene, it has not been possible to assess participants' performance based simply on the % BCR-ABL1/reference gene data reported. Since a single scoring system that can be applied to all participants is required, we used a quantitative approach based upon the log reduction between the % BCR-ABL1/reference gene values for the two samples calculated using the following formula: log10 BCR À ABL1=reference gene ð%Þ Sample1 BCR À ABL1=reference gene ð%Þ Sample2
The log reduction was then used in conjunction with a robust mean and robust standard deviation to calculate an individualised z score for each participant using the following formula:
where x is the log reduction calculated from results returned by the testing laboratory, X is the assigned value (robust mean) andr is the standard deviation for proficiency assessment (robust SD). The robust mean and robust SD were derived from participant data using Algorithm A (ISO, 1998) . This ensured that all participant data was included in The data used in this study was taken from trial data submitted to UKNEQAS LI since the programme's inception in 2007 (21 trial issues, 42 samples, 2476 data sets). The transient inclusion of HEL and Jurkat cell-lines alongside K562 and HL60 cells in a number of trial samples meant that the variance of these samples could not be meaningfully compared to the 'standard' cell line mix of K562 and HL60, thus only 32 samples (from 16 trials), manufactured with K562 and HL60s only, are included in the analysis.
Because any error in RT-qPCR is multiplicative, rather than additive, data distributions from RT-qPCR based EQA/ PT testing programmes produce a lognormal distribution, i.e. an asymmetric distribution of results with a strong positive skew (Zel et al, 2007) (Fig 1) . To normalise the distribution and thus enable calculation of variation using parametric methods, log 10 transformation was undertaken. As log-transformed results of below one produce a negative result, and those above one produce a positive result, we applied a constant of one to all participants BCR-ABL1 results prior to transformation (Osborne, 2002) .
Robust statistics (including the exclusion of outliers as per Algorithm A) were then applied to the transformed dataset. In Algorithm A, sample mean and SD is repeatedly recalculated with outliers being identified and transformed at each step to mitigate their distorting effect without losing them from the dataset (ISO, 1998). Co-efficient of variation cv ¼ r l was used to compare dispersion of participant results for different samples, making the data scale insensitive and enabling the comparison of dispersion between samples with vastly different means. Whilst dispersion was calculated using log-transformed data, where a meaningful data midpoint was required medians were used because log-transformed means (geometric means) are difficult to interpret, and back transforming log-transformed means was not recommended because it led to underestimation (Fowler et al, 1998) .
When assessing the correlation between BCR-ABL1 transcript levels and K562 dilutions, only data from participants using ABL1 as a control gene was analysed, as laboratories using different control genes cannot be meaningfully compared, and ABL1 was used by the majority of participants (84Á4%). However, when assessing the correlation between BCR-ABL IS levels and K562 dilution, data from participants using all control genes was used due to the normalising effect of the IS. Furthermore, when comparing the variation in our unconverted and IS datasets, only data from participants that submitted both unconverted and IS data was analysed and all control genes were included in this dataset.
To address the multilevel nature of the data we have used mixed effects models (Singer, 1998) . To compare the variation in our unconverted and IS datasets we used a multivariate mixed model with random intercepts for laboratory identification, and fixed effects for sample identification, in order to provide estimates and significance values. To In order to assess whether the differences between the mean results for different methods of converting to the IS was significant, we used a mixed effects model with a random intercept for laboratory identification, in which both samples and the methods were treated as fixed effects. To compare the resulting mean values we used an F-test.
P-values < 0Á5 were considered statistically significant.
Results
For the 32 evaluable samples, a total of 2333 results were returned by participants (range 28-179 result/sample). Of the total results, 1970 (84Á4%) were calculated using ABL1 as a reference gene. Other reference genes used by participants include GUSB, G6PD, BCR and B2M. The use of ABL1 increased from 77% of participants in trial BCRQ 0801 (February 2008) to 87% of participants in trial BCRQ 151601 (July 2015). As shown in Fig 2A, there was a very high correlation (R 2 = 0Á96) for the unconverted % BCR-ABL1/ABL1 percentage (range 0Á02-25Á7) and the dilution of K562 cells in HL60 cells (0Á002-4Á6%). Distortions away from linearity, due to the underestimation by participants of % BCR-ABL/ABL1 at levels above 10%, were evident in this data set (Fig 2A) , as expected (Cross, 2009) . When variation was assessed in UK NEQAS LI's data set at differing levels of BCR-ABL1 ( Fig 2B) the coefficient of variation (CV) increased at lower transcript levels, and is particularly marked at ≤0Á1% BCR-ABL1/ABL1 (samples that had median % BCR-ABL1/ABL1 ratios of between 0Á03% and 8Á5% had inter-laboratory CVs ranging from 72% down to 24% respectively). Since its development in 2008 the IS has been widely adopted, currently being used by 77Á6% of participants (Fig 3) . IS data is available in all trials where samples can be meaningfully compared, giving a median % BCR-ABL IS (calculated from all participants' results) ranging from 0Á01 to 16Á7 (Fig 4A) . The greater variation seen at lower levels of disease in the unconverted data set is replicated in the IS data set (Fig 4B) . For participants who submitted both unconverted and IS results, the variation in both data sets was compared. When comparing the unconverted values to the IS values we found that the IS values were lower by 0Á137 (t = À5Á54, df = 1518, P < 0Á0001). The within sample standard deviation was lower for the IS values (v 2 = 52Á4, df = 1, P < 0Á0001).
Furthermore, we observed that different methods of converting to the IS produce consistently different median % BCR-ABL IS results trial-on-trial (Fig 5) . The mixed effects model used to assess whether the differences between the sample results for different methods gave an F value of 5Á93 (P < 0Á0001), indicating at least one method is different from the others (Table S1 ). The median results provided by participants using the Qiagen Ipsogen IS MMR kit are the highest followed by participants using a conversion factor derived by sample exchange with the Naples reference laboratory, then those using a conversion factor from sample exchange with Mannheim and finally the Cepheid GeneXpert assay giving the lowest results. Across all trials analysed, the Qiagen Ipsogen IS MMR kit gave results 2Á0-to 7Á3-fold higher than the Cepheid GeneXpert (median 2Á8-fold).
Despite the large number of instruments and kits that are commercially available, all assays have basically performed well, aside from participants using the Roche Lightcycler in conjunction with the G6PD Roche kit (Roche, Basal, Switzerland) who failed to detect BCR-ABL1 in a number of low levels samples (Table S2 ).
Discussion
BCR-ABL1 testing by RT-qPCR involves the extraction of RNA from patient peripheral blood or bone marrow leucocytes, followed by the synthesis of cDNA by reverse transcription. Following this, BCR-ABL1 transcripts are amplified alongside a dilution series (typically a linearised plasmid), also known as a standard curve, containing known number of copies of BCR-ABL1 targets. By comparing the amplification in a patient sample to that of the standard curve, the number BCR-ABL1 molecules in the patient sample can be inferred. The number of BCR-ABL1 copies is then normalised to the number of transcripts of a reference gene (most commonly ABL1, GUSB or BCR) to control for sample quality, RNA integrity and the efficiency of cDNA synthesis. The ratio of BCR-ABL1 to reference gene copy number is calculated and expressed as a percentage; if BCR-ABL1 is undetectable the reference gene copy number (in the same volume of cDNA used to test for BCR-ABL1) serves as an indicator of the sensitivity with which BCR-ABL1 can be excluded. The inter-laboratory variation seen in BCR-ABL1 measurement is, to some extent, inherent to the procedure: error in RT-qPCR is multiplicative as opposed to additive; the individual error of two separate measurands is effectively compounded (BCR-ABL1 and reference gene); and the complex, multi-step, indirect measurement is vulnerable to error at each step. However, some of the variation emanates from methodological differences taken by different laboratories; everything from primer/probe sets, reference genes and analytical procedures all have the potential to contribute to variation in results.
Optimal response in CML, as defined by the European LeukaemiaNet (Baccarani et al, 2013) , is the achievement of MMR (≤0Á1% BCR-ABL levels, this is particularly marked in samples with levels of disease around MMR. Clearly, there is a risk of misclassifying the success or failure of any treatment at a particular time point, and in practice most haematologists consider trends of residual disease over time in addition to levels of disease at fixed points. Our data show that variation continues to increase as samples approach MR 4.0 , questioning the ability of RT-qPCR to provide accurate data at deep molecular response (Fig 4B) . It is likely therefore that the eligibility criteria for consideration of treatment cessation will require the demonstration of deep molecular response over multiple time-points in order to minimise the effects of intrinsically inaccurate measurements. It is questionable whether RT-qPCR has the intrinsic ability to deliver the substantial improvements. The AE1Á2-fold average difference between reference laboratory and field laboratory post-conversion when generating a laboratory-specific conversion factor may represent the maximum that can be achieved as this is similar to reported intra-laboratory variation for RT-qPCR (Branford et al, 2008) . Many have speculated that digital PCR (dPCR) may further improve sensitivity and overcome some of the variability inherent to RT-qPCR, particularly when measuring very low disease levels. This is because dPCR does not rely on an indirect relationship between cycle threshold of a patient sample and calibration curve to quantify BCR-ABL1 levels, a complex approach vulnerable to error. Instead it is a direct measurement of the number of copies of the original target molecule. Whilst initial data certainly looks encouraging (Andersen & Pallisgaard, 2014; Jennings et al, 2014) a definitive large scale multi-centre study comparing RT-qPCR and dPCR has yet to be published. The potential of dPCR is exemplified by data from the Imatinib Suspension and Validation (ISAV) trial. In this study, the authors achieved a sensitivity of 10
À7
showing a relationship between dPCR positivity and risk of relapse particularly when interpreted in the context of patient age (Mori et al, 2015) .
The IS was conceived to allow laboratories to relate local results to those of large international studies and guidelines. Initially, a laboratory-specific conversion factor derived by sample exchange was the only method available to laboratories to convert to the IS; however, following the production of the first WHO International Genetic Reference Panel for quantification of BCR-ABL1 mRNA (White et al, 2010) , a number of secondary standards and kits calibrated to the primary WHO panel became available, and were adopted by many laboratories as an alternative to converting to the IS (Fig 3) .
The rapid adoption of the IS illustrates that internationally there is recognition of the clinical benefits of an IS-converted result; the lower variation we have demonstrated in our IS dataset compared to the unconverted dataset provides reassurance that the considerable resource invested in the IS has been beneficial. The phenomenon whereby different modes of converting to the IS (whether it be based on a conversion factor or commercial kit) produce consistently different median results is worthy of further investigation (Fig 5) . This information points to imperfections in the processes of converting BCR-ABL1 measurements to the IS. A major issue with the IS results from the lack of readily available, accurately calibrated reagents that can be used to validate the accuracy of any approach; in the absence of such reagents it is unclear what the 'correct' result is for any individual test sample. The recent development of a secondary reference panel (Cross et al, 2016) that faithfully replicates the primary standards, in constitution and manufacture, may go some way to remedy this. The panel is 'cell-based', not RNA based, thus widening the scope of standardisation to the RNA extraction process. In addition, it is the first panel applicable to BCR and GUSB in addition to ABL1. Innovative approaches to IS conversion (Maes et al, 2016) , using mathematical comparison with EQA data, may also improve access to the IS. The data from this study suggests that, to further refine treatment protocols in CML based on BCR-ABL1 quantification by RT-qPCR, methodological improvements and/or greater inter-laboratory standardisation will be required to increase the precision and accuracy of testing. Alternatively, a switch to new platforms, such as dPCR, may be required to overcome some of the technical limitations of current methodologies.
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